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Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resec-
tion of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently 
observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of pa-
tients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. 
Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of 
the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III 
studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph 
node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use 
the fluoropyrimidine based regimen as control group.
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Introduction
Gastric cancer is the second cause of cancer related death world-
wide, with 988,000 new cases and 736,000 deaths per year.(1) Despite 
decreasing frequency of worldwide, the high incidence of gastric 
cancer is a still major health concern in Eastern countries such as 
Korea and Japan. Complete resection of cancer is the only curative 
treatment for gastric cancer. However, even if complete resection 
is possible, recurrence is so frequent at later.(2) So adjuvant treat-
ment for resectable gastric cancer is needed to increase the survival 
of patients. So many phase II or phase III trials were undertaken 
to detect the role of adjuvant chemotherapy for resectable gastric 
cancer. However until recently published, well designed phase III 
studies,(1,3) there is no consensus about adjuvant chemotherapy 
for gastric cancer. And the clinical practice of the management for 
gastric cancer is so diverse according to countries such as the extent 
of resection of gastric cancer, whether inclusion of radiotherapy or 
not, and timing of adjuvant chemotherapy. The D2 dissection is 
traditionally considered as standard treatment in Eastern countries. 
However western countries usually prefer to do dissection of lymph 
nodes with less than D2 dissection due to result of early Dutch trial 
that showed no benefit of D2 dissection.(3) However, long term 
follow up Dutch trials showed a reduction of cancer related death 
with surgery with D2 dissection.(4) Taiwanese study also supported 
benefit of D2 lymph node dissection for gastric cancer.(5) These 
studies supported rationale for the D2 dissection of gastric cancer 
worldwide when D2 surgery is done by experienced surgeons.(6) 
With recently published, well designed phase III trials for D2 dis-
section for gastric cancer and large scaled, patient’s data driven. 
This study wants to describe the role of adjuvant chemotherapy for 
resectable gastric cancer with updated data of recent studies not the Oh SC
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radiotherapy or perioperative chemotherapy. 
Meta-Analysis of Adjuvant Chemotherapy
Several groups published the meta-analysis of data of adjuvant 
chemotherapy for gastric cancer for decades.(3,4,7-12) Hermans 
et al.(13) did not demonstrate the significant benefit of adjuvant 
chemotherapy versus surgery alone (odd ratio [OR] 0.88, 95% con-
fidence interval [CI] 0.72~1.08),(14) However authors re-analysis 
the data including two important studies and demonstrated the 
significance (OR 0.82, 95% CI 0.68~0.97). Earle and Maroun(7) 
investigated using only western population the benefit of adju-
vant chemotherapy for the gastric cancer, they demonstrated the 
significant benefit of survival of adjuvant chemotherapy versus 
surgery alone (OR 0.8, 95% CI 0.66~0.97). The Global Advanced/
Adjuvant Stomach Tumor Research International Collaboration 
(GASTRIC) group published result of meta-analysis of individual 
patient data from 17 trials (3,838 patients) with median follow up 
exceeding 7 years.(3) They collected the data of patients from 17 
trials and updated the survival status and date of last follow-up. 
They demonstrated that adjuvant chemotherapy was associated 
with a statistically significant benefit with overall survival (hazard 
ratio [HR] 0.82, 95% CI 0.76~0.90) and disease free survival (HR 
0.82, 95% CI 0.75~0.90), In terms of analysis of regimens, they 
showed a statistically significant benefit of adjuvant monochemo-
therapy over surgery alone (HR 0.60, 95% CI 0.42~0.84; P=0.03). 
With polychemotherapies of fluorouracil, mitomycin C, and others 
without anthracyclines, the statistically significant benefit for overall 
survival was observed (HR 0.74, 95% CI 0.58~0.95; P=0.03). Poly-
chemotherapies with fluorouracil, Mitomycin C, and anthracyclines 
demonstrated a significant HR reduction of overall survival (HR 
0.82, 95% CI, 0.71~0.96; P=0.01), however other polychemothera-
pies group did not detecte a significant effect of adjuvant regimens 
versus surgery alone (HR 0.89, 95% CI 0.78~1.02; P=0.09). Based 
on these data, they suggested the fluoropyrimidines based regimen 
seems reasonable regimen options.(3)
The recently published meta-analysis studies suggest the benefit 
of adjuvant chemotherapy for gastric cancer, however they did not 
demonstrate consensus of chemotherapeutic regimen, schedule, and 
duration of treatment for adjuvant chemotherapy for gastric cancer. 
Previous large scaled phase III Japanese trial with mitomycin 
C, fluorouracil, and followed oral UFT, a combination of tegafur, 
a prodrug of 5-fluorouracil (5-FU) and uracil treatment did not 
show significant difference between two groups.(15) They consid-
ered that negative result was from high proportion of T1 patients 
in their patients, because at these staged patients, the surgery alone 
yields a very good survival rate and there seemed no need for ad-
juvant therapy. The authors concluded that patients with T1 staged 
patients with gastric cancer should be excluded from further adju-
vant chemotherapy trial, after that, following trials usually excluded 
these stage patients.
Adjuvant Chemotherapy for Extended 
Surgery Using D2 Lymph Node Dissection
The role of adjuvant chemotherapy for resectable gastric cancer 
was still remained to be answer to question, because so many pre-
vious phase III studies did not clearly show the benefit of adjuvant 
chemotherapy in case of D2 lymph node dissection setting. Previ-
ous studies usually did not enroll enough number of patients and 
included early stage patients.(16)
In Japan and Korea, D2 lymph node dissection was considered 
as standard treatment for early gastric cancer. Until the Adjuvant 
Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) study, 
there were no well designed, large number patients enrolled phase 
III studies that show a significant benefit of adjuvant chemotherapy 
for gastric patients with D2 lymph node dissection.(17) The ACTS-
GC study group demonstrated that adjuvant chemotherapy with 1 
year treatment of S-1, oral fluoropyrimidine showed a significant 
benefit for gastric cancer with stage II and III who underwent gas-
trectomy with extended (D2) lymph node dissection.(17) The HR 
for death the S-1 treatment group, as compared with the surgery 
Table 1. Meta-analysis of adjuvant chemotherapy for resectable gastric cancer
Author Year Number of trials Number of patients HR for overall survival (95% CI)
Mari et al.(10) 2000 20 3,658 0.82 (0.75~0.89)
Zhao and Fang(11) 2008 15 3,212 0.90 (0.84~0.96)
Liu et al.(12) 2008 19 4,599 0.85 (0.80~0.90)
GASTRIC group(3) 2010 17 3,838 0.82 (0.76~0.90)
HR = hazard ratio; CI = confidence interval.Adjuvant Chemotherapy for Gastric Cancer
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alone group, was 0.68 (95% CI 0.52~0.87, P=0.003), the primary 
end point was overall survival, the 3 year overall survival rate was 
80% in the S-1 group (95% CI 76.1~84.0) and 70.1% in the sur-
gery only group (95% CI 0.50~0.77; P＜0.001). This study showed 
significant difference at 3 year overall survival. This study was first 
well designed, large scale study to demonstrate a benefit of adjuvant 
chemotherapy for gastric cancer with extended resection. However 
there is still issue about the regimen for adjuvant chemotherapy. 
Because S-1 monotherapy has not shown satisfied activity againist 
advanced gastic cancer. The reason that S-1 monotherapy showed 
effectiveness at adjuvant chemotherapy againist gastric cancer 
should be defined with further treatment. There are some oppor-
tunities to use recently introduced drug regimens that showed high 
activity to advanced gastric cancer as adjuvant chemotherapeutic 
drug. The duration of adjuvant treatment should be confirmed with 
further trials, because only 65% of patients who allocated on adju-
vant chemotherapy remained on drug treatment.
In Korea, clinical trial with using a different regimen for ad-
juvant chemotherapy for the patients with gastric cancer was tried 
and recently published; Bang et al.(1) studied role of adjuvant che-
motherapy against patients with gastric cancer who underwent D2 
extended lymph node dissection using capecitabine and oxaliplatin 
combination treatment compared with surgery alone. This study 
demonstrated adjuvant chemotherapy was effective to at adjuvant 
setting against patients with gastric cancer. They enrolled patients 
with stage II~IIIB gastric cancer who had curative D2 resection. 
The primary endpoint was 3 year disease free survival, there is 
controversy about 3 year disease free survival as primary endpoints 
of resectable gastric cancer that used at The capecitabine and ox-
aliplatin adjuvant study in stomach cancer (CLASSIC) study, was 
not yet formally validated. However recently using GASTRIC data, 
Rougier and Sakamoto(18) showed that 3 year disease free survival 
was strongly correlated with 5 year overall survival and disease free 
survival was shown to be a relevant surrogate of overall survival. 
They collected 1,035 patients who were randomly assigned to re-
ceive either oxaliplatin/capecitabine combination group (n=520) or 
surgery (n=515). 3 year disease free survival was higher in the che-
motherapy group than in the surgery alone group (HR 0.56, 95% CI 
0.44~0.72; P＜0.0001),(1) 3 year disease free survival was 74% (95% 
CI 67~79) in the chemotherapy group and 59% (95% CI 53~64) 
in the surgery only group. In subgroup analysis, they showed the 
significant benefit through at all disease stage (II, III, and IIIB) that 
was not demonstrated at ACTS-GC study and patients with further 
nodal involvement could be more benefit (N2＞N1＞N0). The 
result of 3 year survival was not significant different with HR 0.72 
(95% CI 0.52~1.00; P=0.0493), longer follow-up are need to show 
the significant benefit. In terms of safety profile, frequency of grade 
3~4 adverse events was high compared with that of ACTS-GC 
but comparable to that of colon cancer studies,(19) most common 
were neutropenia (22%), thrombocytopenia (8%), and vomiting 
(7%). However 56% of patients experienced at least one grade 3~4 
adverse events and 10% of patients discontinued chemotherapy due 
to adverse events in the chemotherapy group. Close monitoring of 
patient’s status should be warranted.
Conclusions
Recently published studies supported that adjuvant chemo-
therapy could be benefit for resectable gastric cancer with extended 
lymph node dissection. However further clinical trials should be 
undertaken to make a consensus which regimen is better than 
others, time duration of adjuvant chemotherapy, and how to apply 
with multimodal treatment options. Further phase III trials to de-
termine the best regimen and schedule of adjuvant chemotherapy 
was suggested to use the fluoropyrimidine based regimen as a con-
trol group.
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